Edgestream Partners L.P. Makes New $231,000 Investment in ICU Medical, Inc. (NASDAQ:ICUI)

Edgestream Partners L.P. bought a new stake in ICU Medical, Inc. (NASDAQ:ICUI) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,947 shares of the medical instruments supplier’s stock, valued at approximately $231,000.

A number of other institutional investors have also modified their holdings of the stock. Innealta Capital LLC acquired a new position in ICU Medical in the second quarter valued at $32,000. Motco acquired a new stake in ICU Medical during the first quarter worth about $29,000. GAMMA Investing LLC increased its stake in ICU Medical by 75.1% during the first quarter. GAMMA Investing LLC now owns 310 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 133 shares during the last quarter. EntryPoint Capital LLC increased its stake in ICU Medical by 731.5% during the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock worth $48,000 after acquiring an additional 395 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in ICU Medical by 46.4% during the first quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock worth $59,000 after acquiring an additional 173 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insider Buying and Selling

In related news, VP Virginia Ruth Sanzone sold 2,050 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $144.11, for a total transaction of $295,425.50. Following the completion of the transaction, the vice president now owns 4,482 shares of the company’s stock, valued at approximately $645,901.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,050 shares of the company’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total value of $295,425.50. Following the completion of the transaction, the vice president now owns 4,482 shares of the company’s stock, valued at approximately $645,901.02. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Daniel Woolson sold 2,502 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the transaction, the vice president now directly owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. The disclosure for this sale can be found here. In the last 90 days, insiders sold 28,552 shares of company stock valued at $4,537,802. Insiders own 6.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on ICUI shares. KeyCorp increased their target price on ICU Medical from $136.00 to $147.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Thursday, September 12th. Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research note on Thursday, August 8th. Finally, Raymond James increased their target price on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $149.00.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $175.04 on Tuesday. ICU Medical, Inc. has a fifty-two week low of $78.28 and a fifty-two week high of $181.87. The business has a 50-day moving average of $150.87 and a two-hundred day moving average of $122.12. The stock has a market capitalization of $4.27 billion, a P/E ratio of -71.44 and a beta of 0.65. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 1.08.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.56. ICU Medical had a positive return on equity of 5.01% and a negative net margin of 3.07%. The business had revenue of $596.50 million during the quarter, compared to analysts’ expectations of $556.64 million. During the same quarter in the previous year, the firm earned $1.58 EPS. The firm’s revenue was up 8.6% compared to the same quarter last year. On average, equities research analysts predict that ICU Medical, Inc. will post 3.76 EPS for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.